E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 9/6/2005 in the Prospect News Biotech Daily.

Acambis retained by Merrill Lynch at neutral

Acambis plc was retained by Merrill Lynch analyst Erica Whittaker at neutral, with a base case price on the stock at 220p, following second-quarter results. In London, Acambis shares Tuesday were down 5.75p, or 2.31%, at 243.25p on volume of 704,528 shares versus the three-month running average of 387,982 shares. In the United States, Acambis shares Tuesday were down $0.25, or 2.67%, at $9.13 on volume of 16,540 shares versus the three-month running average of 25,818.2 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.